ClinicalTrials.gg
CompletedNCT03701763Updated Dec 16, 2024Results posted

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of Apremilast (CC-10004) and Placebo in Psoriasis, sponsored by Amgen. Completed at 99 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
14th of 44
245 · median 103
Started
2018
with 5 others
Phase 3
18 of 44
none open now
Registered
25th of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 14th largest by enrollment, is one of 6 that started in 2018, is one of 18 in phase 3, and was the 25th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.

At least 230 pediatric subjects (ages 6 through 17 years) will be randomized 2:1 to receive either apremilast or placebo for the first 16 weeks and then all subjects will receive apremilast during the 36 week Extension Phase for a total of 52 weeks. Randomization to apremilast arm or placebo arm will be stratified by age group (6 to 11 years or 12 to 17 years). Subjects will receive apremilast treatment of either 20 mg twice daily (BID) or 30 mg BID, depending on weight. This Phase 3 study is being conducted to evaluate the safety and efficacy of apremilast in the treatment of pediatric subjects.

Read the detailed description

Treatment will be assigned by weight with subjects 20 kg to \< 50 kg receiving apremilast 20 mg BID or placebo BID and subjects ≥ 50 kg receiving apremilast 30 mg BID or placebo BID. Total study duration is up to 71 weeks. Subjects completing all 52 weeks of the treatment and extension phase will be able to enter the Long-term study. Subjects not entering the Long-term study will return for 3 observational follow-up visits, 4, 8 and 14 weeks after last dose of study drug.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Pediatric
  • 6 through 17 years
  • Plaque Psoriasis
  • Psoriasis
  • CC-10004
  • Apremilast
  • Otezla
  • Children
  • Adolescents
  • SPROUT
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or female subjects 6 to 17 years of age, inclusive, at the time the form is signed by the legal guardian
  2. Subjects must have a weight of ≥ 20 kg
  3. Diagnosis of chronic plaque psoriasis for at least 6 months prior to Screening.
  4. Has moderate to severe plaque psoriasis at Screening and Baseline as defined by:

    • PASI score ≥ 12; and
    • Body surface area (BSA) ≥ 10%; and
    • sPGA ≥ 3 (moderate to severe)
  5. Disease inadequately controlled by or inappropriate for topical therapy for psoriasis
  6. Candidate for systemic therapy or phototherapy

Exclusion criteria

Exclusion Criteria:

  1. Guttate, erythrodermic, or pustular psoriasis at Screening and Baseline
  2. Psoriasis flare or rebound within 4 weeks prior to Screening
  3. Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or randomization in the study, or major psychiatric illness requiring hospitalization within 3 years prior to signing the assent and
  4. Answer "Yes" to any question on the Columbia-Suicide Severity Rating Scale during Screening or at Baseline
  5. Current or planned concurrent use of the following therapies that may have a possible effect on psoriasis

    a. Topical therapy within 2 weeks prior to randomization (including but not limited to topical , topical retinoid or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin/dithranol)

    Exceptions*:

    i. Low potency or weak corticosteroids (please refer to the Investigators' Manual) will be allowed as background therapy for treatment of the face, axillae and groin in accordance with manufacturer's suggested usage ii. Unmedicated skin moisturizer (eg, Eucerin®) will also be permitted for body lesions

    *Subjects should not use these topical treatments within 24 hours prior to the clinic visit.

    b. Conventional systemic therapy for psoriasis within 4 weeks prior to randomization c. Phototherapy treatment (ie, ultraviolet B [UVB], PUVA) within 4 weeks prior to randomization d. Biologic therapy within 4 weeks prior to randomization or 5 PK/PD half-lives (whichever is longer).

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Administration of Apremilast (CC-10004) - 20mg

    Apremilast 20mg Twice Daily (BID)

    Drug: Apremilast (CC-10004)

  • Experimental
    Administration of Apremilast (CC-10004) - 30mg

    Apremilast 30mg Twice Daily (BID)

    Drug: Apremilast (CC-10004)

  • Placebo comparator
    Administration of Placebo

    Placebo tablet Twice Daily (BID)

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16

    The sPGA is the assessment by the Investigator of the overall disease severity of plaque psoriasis at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. The results presented are for the percentage of participants with a sPGA response. An sPGA response was defined as a score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline at Week 16.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved At Least 75% Reduction in Psoriasis Area Severity Index (PASI-75) From Baseline at Week 16

    The Psoriasis Area Severity Index (PASI) is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. The results presented are for the percentage of participants with PASI-75. PASI-75 was defined as at least a 75% reduction in PASI score from baseline.

    Time frame: Baseline and Week 16

  2. Percentage of Participants Who Achieved At Least 50% Reduction in Psoriasis Area Severity Index (PASI-50) From Baseline at Week 16

    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. The results presented are for the percentage of participants with PASI-50. PASI-50 was defined as at least a 50% reduction in PASI score from baseline.

    Time frame: Baseline and Week 16

  3. Percentage Change From Baseline in Total PASI Score at Week 16

    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Positive percentage change from baseline scores indicate a worsening of disease severity, and negative percentage change from baseline scores indicate an improvement in disease severity.

    Time frame: Baseline and Week 16

  4. Percentage Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16

    BSA is a measurement of involved skin of the whole body affected by psoriasis, which ranges from 0% to 100%. Positive percentage change from baseline indicates that a greater BSA was affected by psoriasis. A negative percentage change from baseline indicates that a lesser BSA was affected by psoriasis.

    Time frame: Baseline and Week 16

  5. Percentage of Participants Who Achieved a Children's Dermatology Life Quality Index (CDLQI) Score of 0 or 1 at Week 16

    The CDLQI is designed to measure the impact of skin disease on children's quality of life. The CDLQI measures how much the participant's psoriasis has affected them over the last week, and includes 10 questions with possible answers ranging from not at all (score of 0) to very much (score of 3). The CDLQI total score ranged from 0 (no effect on the participant's life) to 30 (extremely large effect on the participant's life). The results presented are for the percentage of participants who achieved a total CDLQI score of 0 or 1 at Week 16.

    Time frame: Week 16

  6. Change From Baseline in CDLQI Score at Week 16

    The CDLQI is designed to measure the impact of skin disease on children's quality of life. The CDLQI measures how much the participant's psoriasis has affected them over the last week, and includes 10 questions with possible answers ranging from not at all (score of 0) to very much (score of 3). The CDLQI total score ranged from 0 (no effect on the participant's life) to 30 (extremely large effect on the participant's life). A positive change from baseline score indicates that a participant's quality of life has worsened. A negative change from baseline score indicates that a participant's quality of life has improved.

    Time frame: Baseline and Week 16

  7. Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) During the Placebo-controlled Phase

    An adverse event (AE) was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of the study. A TEAE is any AE that occurred after first dose of the investigational product.

    Time frame: 16 weeks

  8. Number of Participants Who Experienced a TEAE During the Apremilast Exposure Period

    An AE was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of the study. A TEAE is any AE that occurred after first dose of the investigational product.

    Time frame: 52 weeks

  9. Number of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE) During the Placebo-controlled Phase

    A TESAE is any AE occurring at any dose after first dose that results in death, is life-threatening (ie, in the opinion of the Investigator, the participant is at immediate risk of death from the AE), requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay), results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions), is a congenital anomaly/birth defect, or constitutes an important medical event.

    Time frame: 16 weeks

  10. Number of Participants Who Experienced a TESAE During the Apremilast Exposure Period

    A TESAE is any AE occurring at any dose after first dose that results in death, is life-threatening (ie, in the opinion of the Investigator, the participant is at immediate risk of death from the AE), requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay), results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions), is a congenital anomaly/birth defect, or constitutes an important medical event.

    Time frame: 52 weeks

  11. Number of Participants Who Experienced a Treatment-related Adverse Event (TRAE) During the Placebo-controlled Phase

    A TREAE is any AE that is determined by the Investigator to have a possibly causal relationship to the investigational product.

    Time frame: 16 weeks

  12. Number of Participants Who Experienced a TRAE During the Apremilast Exposure Period

    A TREAE is any AE that is determined by the Investigator to have a possibly causal relationship to the investigational product.

    Time frame: 52 weeks

  13. Number of Participants With Diarrhea During the Placebo-controlled Phase

    Diarrhea was defined as having 3 or more liquid or watery stools in a day. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.

    Time frame: Up to approximately 113 days

  14. Number of Participants With Diarrhea During the Apremilast Exposure Period

    Diarrhea was defined as having 3 or more liquid or watery stools in a day. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.

    Time frame: Day 1 up to approximately 365 days

  15. Number of Participants With Diarrhea Symptoms During the Placebo-controlled Phase

    Diarrhea symptoms were nausea, vomiting, abdominal cramps, abdominal pain, fever, bloating, and other symptoms. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.

    Time frame: Up to approximately 113 days

  16. Number of Participants With Diarrhea Symptoms During the Apremilast Exposure Period

    Diarrhea symptoms were nausea, vomiting, abdominal cramps, abdominal pain, fever, bloating, and other symptoms. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.

    Time frame: Day 1 up to approximately 365 days

  17. Number of Participants With Suicidal Ideation or Behavior Per the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Placebo-controlled Phase

    The C-SSRS is a questionnaire that is used to assess suicidal ideation and behavior. The C-SSRS questionnaire measures suicidal ideation, intensity of ideation, and suicidal behaviors. Results presented are for the number of participants who recorded suicidal ideation or behavior on the C-SSRS.

    Time frame: 16 weeks

  18. Number of Participants With Suicidal Ideation or Behavior Per the C-SSRS During the Apremilast-extension Phase

    The C-SSRS is a questionnaire that is used to assess suicidal ideation and behavior. The C-SSRS questionnaire measures suicidal ideation, intensity of ideation, and suicidal behaviors. Results presented are for the number of participants who recorded suicidal ideation or behavior on the C-SSRS.

    Time frame: Week 16 to Week 52

  19. Number of Female Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development

    The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the breasts, genitals, testicular volume, and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.

    Time frame: Week 52

  20. Number of Male Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development

    The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the breasts, genitals, testicular volume, and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.

    Time frame: Week 52

  21. Mean Body Weight of Participants During the Placebo-controlled Phase

    The participants' body weight in kilograms (kg) was recorded.

    Time frame: Baseline and Week 16

  22. Mean Body Weight of Participants During the Apremilast Exposure Period

    The participants' body weight in kilograms (kg) was recorded.

    Time frame: Baseline and Week 52

  23. Mean Height of Participants During the Placebo-controlled Phase

    The participants' height in centimeters (cm) was recorded.

    Time frame: Baseline and Week 16

  24. Mean Height of Participants During the Apremilast Exposure Period

    The participants' height in centimeters (cm) was recorded.

    Time frame: Baseline and Week 52

  25. Mean Body Mass Index (BMI) of Participants During the Placebo-controlled Phase

    The participants' BMI was calculated as body weight (kg)/height (m\^2).

    Time frame: Baseline and Week 16

  26. Mean BMI of Participants During the Apremilast Exposure Period

    The participants' BMI was calculated as body weight (kg)/height (m\^2).

    Time frame: Baseline and Week 52

  27. Number of Participants Who Experienced a Psoriasis Flare During the Placebo-controlled Phase

    A psoriasis flare was defined as a sudden intensification of psoriasis (new generalized erythrodermic, inflammatory or pustular psoriasis) requiring medical intervention beyond allowable medications.

    Time frame: 16 weeks

  28. Number of Participants Who Experienced a Psoriasis Flare During the Apremilast Exposure Period

    A psoriasis flare was defined as a sudden intensification of psoriasis (new generalized erythrodermic, inflammatory or pustular psoriasis) requiring medical intervention beyond allowable medications.

    Time frame: 52 weeks

  29. Number of Participants Who Experienced a Psoriasis Rebound

    A psoriasis rebound was defined as an adverse event of psoriasis that started after the last dose date for participants who received treatment in the study.

    Time frame: 14 weeks post last dose (max mean treatment duration in placebo-controlled phase was 15.3 weeks, and 41.9 weeks in the apremilast-exposure period)

07

Results

Posted Dec 7, 2023

Participant flow

Participants were enrolled into this study at sites in Belgium, Canada, Czech Republic, France, Israel, Italy, Russia, Spain, and the United States.

Placebo-controlled Phase
Participant flow — Placebo-controlled Phase
MilestonePlaceboApremilastPlacebo/ApremilastApremilast/Apremilast
Started8216300
Took at least 1 dose of investigational product (ip)8016300
Completed7214900
Not completed101400
Withdrew: Adverse event1500
Withdrew: Lack of efficacy2000
Withdrew: Miscellaneous2000
Withdrew: Withdrawal by parent/guardian3500
Withdrew: Lost to follow-up0100
Withdrew: Withdrawal by subject2300
Apremilast Extension Phase
Participant flow — Apremilast Extension Phase
MilestonePlaceboApremilastPlacebo/ApremilastApremilast/Apremilast
Started0072149
Received apremilast 20mg bid in either placebo-controlled or apremilast extension phases (week 0-52)003680
Received apremilast 30mg bid in either placebo-controlled or apremilast extension phases (week 0-52)003683
Took at least 1 dose of ip0072149
Completed0061125
Not completed001124
Withdrew: Withdrawal by subject0013
Withdrew: Lack of efficacy0038
Withdrew: Adverse event0031
Withdrew: Miscellaneous0021
Withdrew: Withdrawal by parent/guardian0018
Withdrew: Lost to follow-up0002
Withdrew: Non-compliance with study drug0011
14-Week Observational Follow-up Phase
Participant flow — 14-Week Observational Follow-up Phase
MilestonePlaceboApremilastPlacebo/ApremilastApremilast/Apremilast
Started141426
Completed131123
Not completed0133
Withdrew: Miscellaneous0010
Withdrew: Withdrawal by parent/guardian0110
Withdrew: Other0010
Withdrew: Lost to follow-up0001
Withdrew: Withdrawal by subject0002

Outcome measures

PrimaryPercentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16

The sPGA is the assessment by the Investigator of the overall disease severity of plaque psoriasis at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. The results presented are for the percentage of participants with a sPGA response. An sPGA response was defined as a score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline at Week 16.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16
percentage of participantsPlaceboApremilast
Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 1611.533.1
Statistical analysis
  • Placebo vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage adjusted difference: 21.7 · 95% CI 11.2 to 32.1
SecondaryPercentage of Participants Who Achieved At Least 75% Reduction in Psoriasis Area Severity Index (PASI-75) From Baseline at Week 16

The Psoriasis Area Severity Index (PASI) is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. The results presented are for the percentage of participants with PASI-75. PASI-75 was defined as at least a 75% reduction in PASI score from baseline.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved At Least 75% Reduction in Psoriasis Area Severity Index (PASI-75) From Baseline at Week 16
percentage of participantsPlaceboApremilast
Percentage of Participants Who Achieved At Least 75% Reduction in Psoriasis Area Severity Index (PASI-75) From Baseline at Week 1616.145.4
Statistical analysis
  • Placebo vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage adjusted difference: 29.4 · 95% CI 17.8 to 40.9
SecondaryPercentage of Participants Who Achieved At Least 50% Reduction in Psoriasis Area Severity Index (PASI-50) From Baseline at Week 16

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. The results presented are for the percentage of participants with PASI-50. PASI-50 was defined as at least a 50% reduction in PASI score from baseline.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved At Least 50% Reduction in Psoriasis Area Severity Index (PASI-50) From Baseline at Week 16
percentage of participantsPlaceboApremilast
Percentage of Participants Who Achieved At Least 50% Reduction in Psoriasis Area Severity Index (PASI-50) From Baseline at Week 1632.170.5
Statistical analysis
  • Placebo vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage adjusted difference: 38.4 · 95% CI 25.6 to 51.2
SecondaryPercentage Change From Baseline in Total PASI Score at Week 16

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Positive percentage change from baseline scores indicate a worsening of disease severity, and negative percentage change from baseline scores indicate an improvement in disease severity.

Time frame:
Baseline and Week 16
Reported as:
Mean · percentage change
Percentage Change From Baseline in Total PASI Score at Week 16
percentage changePlaceboApremilast
Percentage Change From Baseline in Total PASI Score at Week 16-37.49 ± 3.866-64.52 ± 2.543
Statistical analysis
  • Placebo vs Apremilast · ANCOVA · p = <0.0001 · Difference in least squares mean: -26.97 · 95% CI -35.93 to -18.00
SecondaryPercentage Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16

BSA is a measurement of involved skin of the whole body affected by psoriasis, which ranges from 0% to 100%. Positive percentage change from baseline indicates that a greater BSA was affected by psoriasis. A negative percentage change from baseline indicates that a lesser BSA was affected by psoriasis.

Time frame:
Baseline and Week 16
Reported as:
Mean · percentage change in affected BSA
Percentage Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16
percentage change in affected BSAPlaceboApremilast
Percentage Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16-20.56 ± 5.441-55.44 ± 3.428
Statistical analysis
  • Placebo vs Apremilast · ANCOVA · p = < 0.0001 · Difference in least squares mean: -34.77 · 95% CI -46.99 to -22.55
SecondaryPercentage of Participants Who Achieved a Children's Dermatology Life Quality Index (CDLQI) Score of 0 or 1 at Week 16

The CDLQI is designed to measure the impact of skin disease on children's quality of life. The CDLQI measures how much the participant's psoriasis has affected them over the last week, and includes 10 questions with possible answers ranging from not at all (score of 0) to very much (score of 3). The CDLQI total score ranged from 0 (no effect on the participant's life) to 30 (extremely large effect on the participant's life). The results presented are for the percentage of participants who achieved a total CDLQI score of 0 or 1 at Week 16.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Children's Dermatology Life Quality Index (CDLQI) Score of 0 or 1 at Week 16
percentage of participantsPlaceboApremilast
Percentage of Participants Who Achieved a Children's Dermatology Life Quality Index (CDLQI) Score of 0 or 1 at Week 1631.335.4
Statistical analysis
  • Placebo vs Apremilast · Cochran-Mantel-Haenszel · p = 0.5616 · Percentage adjusted difference: 4.1 · 95% CI -9.8 to 18.0
SecondaryChange From Baseline in CDLQI Score at Week 16

The CDLQI is designed to measure the impact of skin disease on children's quality of life. The CDLQI measures how much the participant's psoriasis has affected them over the last week, and includes 10 questions with possible answers ranging from not at all (score of 0) to very much (score of 3). The CDLQI total score ranged from 0 (no effect on the participant's life) to 30 (extremely large effect on the participant's life). A positive change from baseline score indicates that a participant's quality of life has worsened. A negative change from baseline score indicates that a participant's quality of life has improved.

Time frame:
Baseline and Week 16
Reported as:
Mean · scores on a scale
Change From Baseline in CDLQI Score at Week 16
scores on a scalePlaceboApremilast
Change From Baseline in CDLQI Score at Week 16-2.7 ± 0.56-5.3 ± 0.44
Statistical analysis
  • Placebo vs Apremilast · ANCOVA · p = 0.0009 · Difference in least squares mean: -1.8 · 95% CI -2.9 to -0.8
SecondaryNumber of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) During the Placebo-controlled Phase

An adverse event (AE) was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of the study. A TEAE is any AE that occurred after first dose of the investigational product.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) During the Placebo-controlled Phase
ParticipantsPlaceboApremilast 20mgApremilast 30 mg
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) During the Placebo-controlled Phase335848
SecondaryNumber of Participants Who Experienced a TEAE During the Apremilast Exposure Period

An AE was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of the study. A TEAE is any AE that occurred after first dose of the investigational product.

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a TEAE During the Apremilast Exposure Period
ParticipantsApremilast Exposure Period: Apremilast 20 mg BIDApremilast Exposure Period: Apremilast 30 mg BID
Number of Participants Who Experienced a TEAE During the Apremilast Exposure Period8880
SecondaryNumber of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE) During the Placebo-controlled Phase

A TESAE is any AE occurring at any dose after first dose that results in death, is life-threatening (ie, in the opinion of the Investigator, the participant is at immediate risk of death from the AE), requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay), results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions), is a congenital anomaly/birth defect, or constitutes an important medical event.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE) During the Placebo-controlled Phase
ParticipantsPlaceboApremilast 20mgApremilast 30 mg
Number of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE) During the Placebo-controlled Phase120
SecondaryNumber of Participants Who Experienced a TESAE During the Apremilast Exposure Period

A TESAE is any AE occurring at any dose after first dose that results in death, is life-threatening (ie, in the opinion of the Investigator, the participant is at immediate risk of death from the AE), requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay), results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions), is a congenital anomaly/birth defect, or constitutes an important medical event.

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a TESAE During the Apremilast Exposure Period
ParticipantsApremilast Exposure Period: Apremilast 20 mg BIDApremilast Exposure Period: Apremilast 30 mg BID
Number of Participants Who Experienced a TESAE During the Apremilast Exposure Period21
SecondaryNumber of Participants Who Experienced a Treatment-related Adverse Event (TRAE) During the Placebo-controlled Phase

A TREAE is any AE that is determined by the Investigator to have a possibly causal relationship to the investigational product.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Treatment-related Adverse Event (TRAE) During the Placebo-controlled Phase
ParticipantsPlaceboApremilast 20mgApremilast 30 mg
Number of Participants Who Experienced a Treatment-related Adverse Event (TRAE) During the Placebo-controlled Phase123632
SecondaryNumber of Participants Who Experienced a TRAE During the Apremilast Exposure Period

A TREAE is any AE that is determined by the Investigator to have a possibly causal relationship to the investigational product.

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a TRAE During the Apremilast Exposure Period
ParticipantsApremilast Exposure Period: Apremilast 20 mg BIDApremilast Exposure Period: Apremilast 30 mg BID
Number of Participants Who Experienced a TRAE During the Apremilast Exposure Period4547
SecondaryNumber of Participants With Diarrhea During the Placebo-controlled Phase

Diarrhea was defined as having 3 or more liquid or watery stools in a day. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.

Time frame:
Up to approximately 113 days
Reported as:
Count of participants · Participants
Number of Participants With Diarrhea During the Placebo-controlled Phase
ParticipantsPlaceboApremilast
Day 1 to 282567
Day 29 to 562051
Day 57 to 841441
Day 85 to 1121029
Day >/= 11329
SecondaryNumber of Participants With Diarrhea During the Apremilast Exposure Period

Diarrhea was defined as having 3 or more liquid or watery stools in a day. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.

Time frame:
Day 1 up to approximately 365 days
Reported as:
Count of participants · Participants
Number of Participants With Diarrhea During the Apremilast Exposure Period
ParticipantsApremilast Exposure Period: Apremilast 20 mg BIDApremilast Exposure Period: Apremilast 30 mg BID
Day 1 to 283647
Day 29 to 563036
Day 57 to 842232
Day 85 to 1121719
Day 113 to 1402117
Day 141 to 1681621
Day 169 to 1961917
Day 197 to 2241912
Day 225 to 2522012
Day 253 to 2801816
Day 281 to 308139
Day 309 to 336125
Day 337 to 36475
Day >= 36511
SecondaryNumber of Participants With Diarrhea Symptoms During the Placebo-controlled Phase

Diarrhea symptoms were nausea, vomiting, abdominal cramps, abdominal pain, fever, bloating, and other symptoms. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.

Time frame:
Up to approximately 113 days
Reported as:
Count of participants · Participants
Number of Participants With Diarrhea Symptoms During the Placebo-controlled Phase
ParticipantsPlaceboApremilast
Day 1 to 28 — Nausea332
Day 1 to 28 — Vomiting213
Day 1 to 28 — Abdominal cramps316
Day 1 to 28 — Abdominal pain928
Day 1 to 28 — Fever15
Day 1 to 28 — Bloating18
Day 1 to 28 — Other symptoms521
Day 1 to 28 — No symptoms5333
Day 29 to 56 — Nausea222
Day 29 to 56 — Vomiting26
Day 29 to 56 — Abdominal cramps37
Day 29 to 56 — Abdominal pain917
Day 29 to 56 — Fever01
Day 29 to 56 — Bloating412
Day 29 to 56 — Other symptoms417
Day 29 to 56 — No symptoms5681
Day 57 to 84 — Nausea112
Day 57 to 84 — Vomiting07
Day 57 to 84 — Abdominal cramps19
Day 57 to 84 — Abdominal pain513
Day 57 to 84 — Fever02
Day 57 to 84 — Bloating26
Day 57 to 84 — Other symptoms611
Day 57 to 84 — No symptoms65103
Day 85 to 112 — Nausea28
Day 85 to 112 — Vomiting13
Day 85 to 112 — Abdominal cramps15
Day 85 to 112 — Abdominal pain27
Day 85 to 112 — Fever02
Day 85 to 112 — Bloating35
Day 85 to 112 — Other symptoms58
Day 85 to 112 — No symptoms66125
Day >/= 113 — Nausea02
Day >/= 113 — Vomiting01
Day >/= 113 — Abdominal cramps01
Day >/= 113 — Abdominal pain02
Day >/= 113 — Fever00
Day >/= 113 — Bloating11
Day >/= 113 — Other symptoms02
Day >/= 113 — No symptoms79154
SecondaryNumber of Participants With Diarrhea Symptoms During the Apremilast Exposure Period

Diarrhea symptoms were nausea, vomiting, abdominal cramps, abdominal pain, fever, bloating, and other symptoms. Participants and their parent/guardian were supplied with diaries (either paper or electronic) that were filled out daily to record and describe any diarrhea and associated symptoms.

Time frame:
Day 1 up to approximately 365 days
Reported as:
Count of participants · Participants
Number of Participants With Diarrhea Symptoms During the Apremilast Exposure Period
ParticipantsApremilast Exposure Period: Apremilast 20 mg BIDApremilast Exposure Period: Apremilast 30 mg BID
Day 1 to 28 — Nausea1721
Day 1 to 28 — Vomiting104
Day 1 to 28 — Abdominal cramps79
Day 1 to 28 — Abdominal pain2114
Day 1 to 28 — Fever23
Day 1 to 28 — Bloating37
Day 1 to 28 — Other symptoms1113
Day 1 to 28 — No symptoms3843
Day 29 to 56 — Nausea1410
Day 29 to 56 — Vomiting43
Day 29 to 56 — Abdominal cramps44
Day 29 to 56 — Abdominal pain138
Day 29 to 56 — Fever10
Day 29 to 56 — Bloating49
Day 29 to 56 — Other symptoms99
Day 29 to 56 — No symptoms5970
Day 57 to 84 — Nausea68
Day 57 to 84 — Vomiting64
Day 57 to 84 — Abdominal cramps83
Day 57 to 84 — Abdominal pain106
Day 57 to 84 — Fever11
Day 57 to 84 — Bloating16
Day 57 to 84 — Other symptoms106
Day 57 to 84 — No symptoms5976
Day 85 to 112 — Nausea35
Day 85 to 112 — Vomiting30
Day 85 to 112 — Abdominal cramps42
Day 85 to 112 — Abdominal pain63
Day 85 to 112 — Fever12
Day 85 to 112 — Bloating24
Day 85 to 112 — Other symptoms54
Day 85 to 112 — No symptoms7686
Day 113 to 140 — Nausea62
Day 113 to 140 — Vomiting51
Day 113 to 140 — Abdominal cramps40
Day 113 to 140 — Abdominal pain73
Day 113 to 140 — Fever10
Day 113 to 140 — Bloating32
Day 113 to 140 — Other symptoms53
Day 113 to 140 — No symptoms6895
Day 141 to 168 — Nausea52
Day 141 to 168 — Vomiting31
Day 141 to 168 — Abdominal cramps21
Day 141 to 168 — Abdominal pain42
Day 141 to 168 — Fever00
Day 141 to 168 — Bloating22
Day 141 to 168 — Other symptoms31
Day 141 to 168 — No symptoms7995
Day 169 to 196 — Nausea34
Day 169 to 196 — Vomiting21
Day 169 to 196 — Abdominal cramps12
Day 169 to 196 — Abdominal pain75
Day 169 to 196 — Fever02
Day 169 to 196 — Bloating01
Day 169 to 196 — Other symptoms70
Day 169 to 196 — No symptoms7687
Day 197 to 224 — Nausea52
Day 197 to 224 — Vomiting50
Day 197 to 224 — Abdominal cramps10
Day 197 to 224 — Abdominal pain31
Day 197 to 224 — Fever20
Day 197 to 224 — Bloating11
Day 197 to 224 — Other symptoms41
Day 197 to 224 — No symptoms7297
Day 225 to 252 — Nausea93
Day 225 to 252 — Vomiting30
Day 225 to 252 — Abdominal cramps21
Day 225 to 252 — Abdominal pain71
Day 225 to 252 — Fever00
Day 225 to 252 — Bloating31
Day 225 to 252 — Other symptoms40
Day 225 to 252 — No symptoms6492
Day 253 to 280 — Nausea54
Day 253 to 280 — Vomiting10
Day 253 to 280 — Abdominal cramps31
Day 253 to 280 — Abdominal pain63
Day 253 to 280 — Fever10
Day 253 to 280 — Bloating21
Day 253 to 280 — Other symptoms32
Day 253 to 280 — No symptoms5558
Day 281 to 308 — Nausea23
Day 281 to 308 — Vomiting12
Day 281 to 308 — Abdominal cramps12
Day 281 to 308 — Abdominal pain42
Day 281 to 308 — Fever00
Day 281 to 308 — Bloating01
Day 281 to 308 — Other symptoms11
Day 281 to 308 — No symptoms5249
Day 309 to 336 — Nausea21
Day 309 to 336 — Vomiting20
Day 309 to 336 — Abdominal cramps10
Day 309 to 336 — Abdominal pain40
Day 309 to 336 — Fever10
Day 309 to 336 — Bloating10
Day 309 to 336 — Other symptoms41
Day 309 to 336 — No symptoms4757
Day 337 to 364 — Nausea21
Day 337 to 364 — Vomiting10
Day 337 to 364 — Abdominal cramps00
Day 337 to 364 — Abdominal pain22
Day 337 to 364 — Fever00
Day 337 to 364 — Bloating10
Day 337 to 364 — Other symptoms11
Day 337 to 364 — No symptoms5254
Day >= 365 — Nausea00
Day >= 365 — Vomiting00
Day >= 365 — Abdominal cramps01
Day >= 365 — Abdominal pain00
Day >= 365 — Fever00
Day >= 365 — Bloating00
Day >= 365 — Other symptoms00
Day >= 365 — No symptoms2421
SecondaryNumber of Participants With Suicidal Ideation or Behavior Per the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Placebo-controlled Phase

The C-SSRS is a questionnaire that is used to assess suicidal ideation and behavior. The C-SSRS questionnaire measures suicidal ideation, intensity of ideation, and suicidal behaviors. Results presented are for the number of participants who recorded suicidal ideation or behavior on the C-SSRS.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation or Behavior Per the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Placebo-controlled Phase
ParticipantsPlaceboApremilast
Number of Participants With Suicidal Ideation or Behavior Per the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Placebo-controlled Phase00
SecondaryNumber of Participants With Suicidal Ideation or Behavior Per the C-SSRS During the Apremilast-extension Phase

The C-SSRS is a questionnaire that is used to assess suicidal ideation and behavior. The C-SSRS questionnaire measures suicidal ideation, intensity of ideation, and suicidal behaviors. Results presented are for the number of participants who recorded suicidal ideation or behavior on the C-SSRS.

Time frame:
Week 16 to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation or Behavior Per the C-SSRS During the Apremilast-extension Phase
ParticipantsApremilast-extension Phase: Apremilast 20 mg BIDApremilast-extension Phase: Apremilast 30 mg BID
Number of Participants With Suicidal Ideation or Behavior Per the C-SSRS During the Apremilast-extension Phase00
SecondaryNumber of Female Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development

The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the breasts, genitals, testicular volume, and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Female Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development
ParticipantsPlaceboApremilast
Breast Growth — Stage 1817
Breast Growth — Stage 239
Breast Growth — Stage 339
Breast Growth — Stage 4620
Breast Growth — Stage 51227
Breast Growth — Missing57
Pubic Hair Growth — Stage 1818
Pubic Hair Growth — Stage 239
Pubic Hair Growth — Stage 339
Pubic Hair Growth — Stage 4618
Pubic Hair Growth — Stage 51228
Pubic Hair Growth — Missing57
Other Changes — Stage 1818
Other Changes — Stage 239
Other Changes — Stage 3312
Other Changes — Stage 4416
Other Changes — Stage 51226
Other Changes — Missing78
SecondaryNumber of Male Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development

The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the breasts, genitals, testicular volume, and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Male Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development
ParticipantsPlaceboApremilast
Testes Growth — Stage 11115
Testes Growth — Stage 255
Testes Growth — Stage 3410
Testes Growth — Stage 4512
Testes Growth — Stage 51427
Testes Growth — Missing45
Penis Growth — Stage 11115
Penis Growth — Stage 255
Penis Growth — Stage 3411
Penis Growth — Stage 4510
Penis Growth — Stage 51428
Penis Growth — Missing45
Pubic Hair Growth — Stage 11015
Pubic Hair Growth — Stage 256
Pubic Hair Growth — Stage 358
Pubic Hair Growth — Stage 4614
Pubic Hair Growth — Stage 51326
Pubic Hair Growth — Missing45
Other Changes — Stage 1915
Other Changes — Stage 255
Other Changes — Stage 348
Other Changes — Stage 4411
Other Changes — Stage 51426
Other Changes — Missing79
SecondaryMean Body Weight of Participants During the Placebo-controlled Phase

The participants' body weight in kilograms (kg) was recorded.

Time frame:
Baseline and Week 16
Reported as:
Mean · kg
Mean Body Weight of Participants During the Placebo-controlled Phase
kgPlaceboApremilast
Baseline52.36 ± 22.17752.04 ± 21.123
Week 1654.18 ± 22.58151.95 ± 20.945
SecondaryMean Body Weight of Participants During the Apremilast Exposure Period

The participants' body weight in kilograms (kg) was recorded.

Time frame:
Baseline and Week 52
Reported as:
Mean · kg
Mean Body Weight of Participants During the Apremilast Exposure Period
kgApremilast Exposure Period: Apremilast 20 mg BIDApremilast Exposure Period: Apremilast 30 mg BID
Baseline36.81 ± 8.95467.94 ± 19.053
Week 5239.04 ± 9.82367.79 ± 18.889
SecondaryMean Height of Participants During the Placebo-controlled Phase

The participants' height in centimeters (cm) was recorded.

Time frame:
Baseline and Week 16
Reported as:
Mean · cm
Mean Height of Participants During the Placebo-controlled Phase
cmPlaceboApremilast
Baseline153.29 ± 18.435153.33 ± 18.069
Week 16154.54 ± 17.839154.40 ± 17.683
SecondaryMean Height of Participants During the Apremilast Exposure Period

The participants' height in centimeters (cm) was recorded.

Time frame:
Baseline and Week 52
Reported as:
Mean · cm
Mean Height of Participants During the Apremilast Exposure Period
cmApremilast Exposure Period: Apremilast 20 mg BIDApremilast Exposure Period: Apremilast 30 mg BID
Baseline140.86 ± 14.159166.13 ± 11.416
Week 52144.90 ± 13.944167.84 ± 10.814
SecondaryMean Body Mass Index (BMI) of Participants During the Placebo-controlled Phase

The participants' BMI was calculated as body weight (kg)/height (m\^2).

Time frame:
Baseline and Week 16
Reported as:
Mean · kg/m^2
Mean Body Mass Index (BMI) of Participants During the Placebo-controlled Phase
kg/m^2PlaceboApremilast
Baseline21.41 ± 5.65221.33 ± 5.197
Week 1621.87 ± 5.88320.98 ± 5.067
SecondaryMean BMI of Participants During the Apremilast Exposure Period

The participants' BMI was calculated as body weight (kg)/height (m\^2).

Time frame:
Baseline and Week 52
Reported as:
Mean · kg/m^2
Mean BMI of Participants During the Apremilast Exposure Period
kg/m^2Apremilast Exposure Period: Apremilast 20 mg BIDApremilast Exposure Period: Apremilast 30 mg BID
Baseline18.32 ± 2.64124.52 ± 5.655
Week 5218.30 ± 2.48023.95 ± 5.539
SecondaryNumber of Participants Who Experienced a Psoriasis Flare During the Placebo-controlled Phase

A psoriasis flare was defined as a sudden intensification of psoriasis (new generalized erythrodermic, inflammatory or pustular psoriasis) requiring medical intervention beyond allowable medications.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Psoriasis Flare During the Placebo-controlled Phase
ParticipantsPlaceboApremilast
Number of Participants Who Experienced a Psoriasis Flare During the Placebo-controlled Phase32
SecondaryNumber of Participants Who Experienced a Psoriasis Flare During the Apremilast Exposure Period

A psoriasis flare was defined as a sudden intensification of psoriasis (new generalized erythrodermic, inflammatory or pustular psoriasis) requiring medical intervention beyond allowable medications.

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Psoriasis Flare During the Apremilast Exposure Period
ParticipantsApremilast Exposure Period: Apremilast 20 mg BIDApremilast Exposure Period: Apremilast 30 mg BID
Number of Participants Who Experienced a Psoriasis Flare During the Apremilast Exposure Period711
SecondaryNumber of Participants Who Experienced a Psoriasis Rebound

A psoriasis rebound was defined as an adverse event of psoriasis that started after the last dose date for participants who received treatment in the study.

Time frame:
14 weeks post last dose (max mean treatment duration in placebo-controlled phase was 15.3 weeks, and 41.9 weeks in the apremilast-exposure period)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Psoriasis Rebound
ParticipantsPlaceboApremilast 20 mg BIDApremilast 30 mg BID
Number of Participants Who Experienced a Psoriasis Rebound004

Adverse events

Collected over Up to a maximum of 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-Controlled Phase: Placebo BID0/82 (0%)1/80 (1.3%)26/80 (32.5%)
Placebo-Controlled Phase: Apremilast 20 mg BID0/80 (0%)2/80 (2.5%)50/80 (62.5%)
Placebo-Controlled Phase: Apremilast 30 mg BID0/83 (0%)0/83 (0%)41/83 (49.4%)
Placebo-Controlled Phase: Apremilast BID0/163 (0%)2/163 (1.2%)91/163 (55.8%)
Apremilast Extension Phase: Apremilast 20 mg BID0/110 (0%)0/110 (0%)52/110 (47.3%)
Apremilast Extension Phase: Apremilast 30 mg BID0/111 (0%)2/111 (1.8%)38/111 (34.2%)
Apremilast Extension Phase: Apremilast BID0/221 (0%)2/221 (0.9%)90/221 (40.7%)
Most frequent serious events
Most frequent serious events
EventPlacebo-Controlled Phase: Placebo BIDPlacebo-Controlled Phase: Apremilast 20 mg BIDPlacebo-Controlled Phase: Apremilast 30 mg BIDPlacebo-Controlled Phase: Apremilast BIDApremilast Extension Phase: Apremilast 20 mg BIDApremilast Extension Phase: Apremilast 30 mg BIDApremilast Extension Phase: Apremilast BID
Iron deficiency anaemiaBlood and lymphatic system disorders0/801/800/831/1630/1100/1110/221
Sinus tachycardiaCardiac disorders0/801/800/831/1630/1100/1110/221
Wandering pacemakerCardiac disorders0/801/800/831/1630/1100/1110/221
Autonomic nervous system imbalanceNervous system disorders0/801/800/831/1630/1100/1110/221
Testicular appendage torsionReproductive system and breast disorders1/800/800/830/1630/1100/1110/221
PsoriasisSkin and subcutaneous tissue disorders0/801/800/831/1630/1100/1110/221
AppendicitisInfections and infestations0/800/800/830/1630/1101/1111/221
Status migrainosusNervous system disorders0/800/800/830/1630/1101/1111/221
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlacebo-Controlled Phase: Placebo BIDPlacebo-Controlled Phase: Apremilast 20 mg BIDPlacebo-Controlled Phase: Apremilast 30 mg BIDPlacebo-Controlled Phase: Apremilast BIDApremilast Extension Phase: Apremilast 20 mg BIDApremilast Extension Phase: Apremilast 30 mg BIDApremilast Extension Phase: Apremilast BID
Abdominal painGastrointestinal disorders8/8023/809/8332/16314/1105/11119/221
DiarrhoeaGastrointestinal disorders8/8015/8017/8332/16320/11013/11133/221
NauseaGastrointestinal disorders2/8015/8017/8332/16318/11010/11128/221
VomitingGastrointestinal disorders2/8016/8013/8329/16315/1107/11122/221
HeadacheNervous system disorders4/8012/805/8317/1637/1105/11112/221
PsoriasisSkin and subcutaneous tissue disorders3/800/802/832/1635/11011/11116/221
PyrexiaGeneral disorders1/807/803/8310/1634/1101/1115/221
DyspepsiaGastrointestinal disorders0/803/807/8310/1632/1102/1114/221
NasopharyngitisInfections and infestations3/805/805/8310/1638/1103/11111/221
Abdominal pain upperGastrointestinal disorders4/805/804/839/1635/1100/1115/221

Baseline characteristics

Measured in the intent-to-treat (ITT) population, which included all participants who were randomized.

Age, Continuous
Age, Continuous(years)PlaceboApremilastTotal
Mean12.2 ± 3.2512.3 ± 3.3212.2 ± 3.29
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApremilastTotal
Female3989128
Male4374117
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboApremilastTotal
Hispanic or Latino82432
Not Hispanic or Latino71129200
Unknown or Not Reported31013
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboApremilastTotal
American Indian or Alaska Native022
Asian369
Native Hawaiian or Other Pacific Islander000
Black or African American358
White73140213
More than one race000
Unknown or Not Reported31013
08

Study locations

99 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35233, United States
  • Phoenix Childrens Hospital
    Phoenix, Arizona 85016, United States
  • Johnson Dermatology Clinic
    Fort Smith, Arkansas 72916, United States
  • Zenith Research Inc.
    Beverly Hills, California 90212, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Avance Clinical Trials
    Laguna Niguel, California 92677, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Coastal Family Dermatology
    San Luis Obispo, California 93401, United States
  • University of California Los Angeles
    Santa Monica, California 90404, United States
  • California Dermatology Institute
    Thousand Oaks, California 91320, United States
  • Solutions Through Advanced Research Inc
    Jacksonville, Florida 32256, United States
  • Glick Skin Institute Clinical Research
    Margate, Florida 33063, United States
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • Ciocca Dermatology
    Miami, Florida 33173, United States
  • University of South Florida Health Morsani Center for Advanced Healthcare
    Tampa, Florida 33612-4742, United States
  • Skin Care Physicians of Georgia
    Macon, Georgia 31217, United States
  • Treasure Valley Medical Research
    Meridian, Idaho 83646, United States
  • DeNova Research
    Chicago, Illinois 60602, United States
  • Dawes Fretzin Dermatology Group Inc
    Indianapolis, Indiana 46256, United States
  • Epiphany Dermatology of Kansas, LLC
    Overland Park, Kansas 66210, United States
  • ActivMed Practices and Research Inc
    Beverly, Massachusetts 01915, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • J Woodson Dermatology and Associates Ltd
    Henderson, Nevada 89052, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03766, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Forest Hills Dermatology Group
    Forest Hills, New York 11375, United States
  • SUNY Downstate Medical Center
    Manhasset, New York 11030, United States
  • Cincinnati Childrens Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Wright State Physicians
    Fairborn, Ohio 45324, United States
  • Essential Medical Research, LLC
    Tulsa, Oklahoma 74137, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Arlington Research Center
    Arlington, Texas 76011, United States
  • Driscoll Childrens Hospital
    Corpus Christi, Texas 78411, United States
  • Modern Research Associates PLLC
    Dallas, Texas 75231, United States
  • Mosaic Dermatology
    Houston, Texas 77065, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Jordan Valley Dermatology Center
    West Jordan, Utah 84088, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53715, United States
  • Childrens Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Centre Hospitalier Universitaire Saint Pierre
    Brussels, 1000, Belgium
  • Cliniques Universitaires St Luc
    Bruxelles, 1200, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • Kirk Barber Research
    Calgary, Alberta T2G 1B1, Canada
  • Stollery Children's Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Enverus Medical Research
    Surrey, British Columbia V3R 6A7, Canada
  • Winnipeg Clinic Dermatology Research
    Winnipeg, Manitoba R3C 0N2, Canada
  • Karma Clinical Trials
    Saint John's, Newfoundland and Labrador A1A 4Y3, Canada
  • AvantDerm
    Toronto, Ontario M5A 3R6, Canada
  • CHU Saint-Justine
    Montreal, Quebec H3T 1C5, Canada
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha 1, 110 00, Czechia
  • Synexus Czech sro
    Praha, 120 00, Czechia
  • Centre Hospitalier Victor Dupouy Argenteuil
    Argenteuil, 95107, France
  • Centre Hospitalier Universitaire Lyon
    Bron cedex, 69677, France
  • Cabinet du Docteur Ruer-Mulard Mireille
    Martigues, 13500, France
  • Hotel Dieu CHU Nantes
    Nantes, 44093, France
  • Centre Hospitalier Universitaire de Nice
    Nice, 06202, France
  • Hopital Necker
    Paris Cedex 15, 75015, France
  • Centre Hospitalier de Cornouaille - Hopital Laennec
    Quimper, 29018, France
  • CHU Saint Etienne Hopital Nord
    Saint-Priest En Jarrez, 42055, France
  • Centre Hospitalier Universitaire de Toulouse - Hopital Larrey
    Toulouse Cedex 9, 31059, France
  • Centre Hospitalier de Valence
    Valence, 26000, France
  • Chaim Sheba Medical Center
    Ramat Gan, 5262000, Israel
  • Azienda Ospedaliero Universitaria Di Bologna Policlinico S Orsola Malpighi
    Bologna, 40138, Italy
  • Azienda Ospedaliera Universitaria di Cagliari
    Cagliari, 09124, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • Azienda Ospedaliera Universitaria Federico II
    Napoli, 80131, Italy
  • Azienda Ospedaliera di Padova
    Padova, 35128, Italy
  • Azienda Ospedaliera di Reggio Emilia Arcispedale Santa Maria Nuova
    Reggio Emilia, 42123, Italy
  • Policlinico Tor Vergata
    Roma, 00133, Italy
  • Istituto Dermatologico San Gallicano IRCCS Dermatologia Clinica
    Roma, 00144, Italy
  • Radboud university medical center
    NIjmegen, Netherlands
  • Altai State Medical University
    Barnaul, 656038, Russian Federation
  • Chelyabinsk Regional Clinical Skin and Venereal Dispensary
    Chelyabinsk, 454092, Russian Federation
  • Ural Scientific Research Institute of Dermatovenereology and Immunopathology
    Ekaterinburg, 620076, Russian Federation
  • Republican Clinical Dermatology and Venerology Dispensary
    Kazan, 420004, Russian Federation
  • Clinical Dispensary of Dermatology and Venereology of Krasnodar Territory of the Ministry of Health
    Krasnodar, 350020, Russian Federation
  • State Scientific Center for Dermatovenereology and Cosmetology
    Moscow, 107076, Russian Federation
  • Russian Children's Clinical Hospital
    Moscow, 117997, Russian Federation
  • Moscow Scientific Practical Center of Dermatology Venerology and Cosmetology
    Moscow, 119071, Russian Federation
  • National Medical Research Center for Children's Health
    Moscow, 119991, Russian Federation
  • LLC Medical Center Zdorovaya Semiya
    Novosibirsk, 630099, Russian Federation
  • Pierre Wolkenshtein Skin Diseases Clinic LLC
    Saint Petersburg, 191123, Russian Federation
  • LLC PiterKlinika
    Saint Petersburg, 196158, Russian Federation
  • Saint Petersburg State Pediatric Medical University
    Saint Petesburg, 194100, Russian Federation
  • Bashkiria State Medical University
    Ufa, 450008, Russian Federation
  • Yarosavl State Medical Academy
    Yaroslavl, 150000, Russian Federation
  • Hospital Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital General Universitario de Alicante
    Alicante, Comunidad Valenciana 03010, Spain
  • Hospital Universitari Germans Trias i Pujol Can Ruti
    Badalona, 08916, Spain
  • Hospital Sant Joan de Deu
    Barcelona, 08950, Spain
  • Hospital Puerta del Mar
    Cadiz, 11009, Spain
  • Hospital Universitario Reina Sofia
    Cordoba, 14001, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Infantil Universitario Nino Jesus
    Madrid, 28009, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital La Paz
    Madrid, 28046, Spain
  • Complexo Hospitalario De Pontevedra
    Pontevedra, 36001, Spain
  • Hospital Universitario Virgen del Rocio - PPDS
    Sevilla, 41013, Spain
09

References and documents

Publications

  • Fiorillo L, Becker E, de Lucas R, Belloni-Fortina A, Armesto S, Elewski B, Maes P, Oberoi RK, Paris M, Zhang W, Zhang Z, Arkin L. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial. J Am Acad Dermatol. 2024 Jun;90(6):1232-1239. doi: 10.1016/j.jaad.2023.11.068. Epub 2024 Jan 23. PubMed 38266683 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Apr 2022, 40 months.

Results were first posted in Dec 2023, 1 year 7 months after primary completion. A results delay was requested in Oct 2022.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 40 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2018
First posted
Oct 10, 2018
StartActual
Dec 19, 2018
Primary completionActual
Apr 25, 2022
CompletionActual
Mar 27, 2023
Results delay requested
Oct 27, 2022
Results first posted
Dec 7, 2023
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03701763
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 10, 2018
Start date
Dec 19, 2018
Primary completion
Apr 25, 2022
Completion
Mar 27, 2023
Results posted
Dec 7, 2023
Last update
Dec 16, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion